Molecure S.A. (FRA:1B1)

Market Cap	41.94M +15.0%
Revenue (ttm)	1.37M +459.1%
Net Income	-5.72M
EPS	-0.25
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	1.996
Previous Close	2.020
Day's Range	1.990 - 1.996
52-Week Range	1.216 - 2.430
Beta	n/a
RSI	74.19
Earnings Date	Mar 26, 2026

About Molecure

Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-4...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 71
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1B1

Financial Performance

In 2024, Molecure's revenue was 2.92 million, a decrease of -20.08% compared to the previous year's 3.65 million. Losses were -31.29 million, 10.3% more than in 2023.

Financial numbers in PLN